MAVENIR
14.12.2021 09:03:17 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today that Vodafone and Mavenir have completed the first data and Voice over LTE (VoLTE) call across a containerised 4G small cell Open RAN solution in a lab environment. The completed tests are the latest steps forward to delivering an open and vendor-interoperable 4G connectivity solution for small to medium-sized office locations.
Having first started work on a containerised indoor enterprise connectivity solution in January 2021, Vodafone has completed tests for an important stage of the technology roadmap. The plug-and-play small cell equipment can ensure comprehensive mobile coverage in every corner of the office. The solution will provide 4G coverage initially, making use of radio hardware from Sercomm and software from Mavenir (Open RAN).
This demonstration of a containerised solution is a major milestone in the evolution of connectivity equipment away from physical infrastructure to a digital cloud-based environment. Containerisation provides greater flexibility for customers, but also significant benefits in terms of speed and cost of deployment.
Containerisation means that software can be seamlessly transferred between equipment, platforms, and applications. Wind River provided its Containers as a Service (CaaS) software, part of Wind River Studio.
Moving forward, Vodafone and Mavenir will focus on finalising the packaging and automation of the solution before beginning trials with selected customers.
Open RAN technology separates software from hardware, meaning more flexibility for mobile operators and customers. The approach will see many companies providing the components that make up a mobile network site, where previously one vendor would have delivered the whole solution. The technology is widely accepted as a disruptor for the telecommunications industry, and Vodafone is one of the industry leaders in supporting the development of this vendor ecosystem.
Whereas much of the focus for Open RAN has been directed towards network infrastructure deployment on mobile sites throughout the UK, the technology can be implemented in an enterprise environment to support local connectivity requirements. As an interoperable and standardised technology, Open RAN solutions can be integrated with little disruption in a “plug and play” manner, interoperable with other Open RAN compliant vendors.
Andrea Dona, Chief Network Officer, Vodafone UK, said ; “Open RAN is opening doors to simplified and intuitive connectivity solutions. For our wider network deployment strategy, Open RAN is enabling us to work with a wider pool of suppliers and to avoid vendor lock-in scenarios that might prevent us from taking advantage of the latest innovations. The same could be said for enterprise connectivity solutions.
“From the moment Open RAN is deployed in an office environment, customers are no-longer locked into a single upgrade path. Working alongside Vodafone, customers can be more flexible in how connectivity solutions are adapted and upgraded as demands evolve in the future.”
Stefano Cantarelli, Executive Vice President and Chief Marketing Officer, Mavenir, said ; “Cloud Native and Open Solutions are becoming the new reality of the mobile world, and these include Radio Access and its containerised implementation. Open vRAN is a very flexible architecture that can serve any type of segment and Mavenir is really pleased to work with Vodafone in the enterprise business and achieved another first together. It is an opportunity to show that automated and AI controlled systems will simplify life to business and industry.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Vodafone UK
Vodafone UK is a technology communications company that connects people, businesses and devices to help our customers benefit from digital innovation. Our services span mobile, fixed-line connections, home and office broadband, and the Internet of Things (IoT). www.vodafone.co.uk
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005101/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
